Abich Financial Wealth Management’s Standard BioTools LAB Stock Holding History

Abich Financial Wealth Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$119K	Buy	+91,448	New	+$120K	0.04%	197

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Abich Financial Wealth Management's LAB Position: Q3 2025 in Review

Abich Financial Wealth Management opened a new position in Standard BioTools (LAB) in Q3 2025: 91,448 shares worth $119K. The stake represents 0.04% of the portfolio and ranks #197 among its holdings.

155 funds tracked by Wall St. Rank hold LAB as of Q3 2025.

Abich Financial Wealth Management held 91,448 shares of Standard BioTools worth $119K as of Q3 2025.
Standard BioTools was a new Abich Financial Wealth Management position in Q3 2025.
Standard BioTools made up 0.04% of Abich Financial Wealth Management's portfolio in Q3 2025, its #197 holding.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2025.

Based on Abich Financial Wealth Management's 13F filing for Q3 2025, filed 6 Nov 2025.